IgG4-Related Disease Market Size Projected to Grow 34.60% by 2034

DelveInsight's report forecasts significant market expansion for IgG4-related disease treatments

Jan. 29, 2026 at 7:39pm

Got story updates? Submit your updates here. ›

DelveInsight's 'IgG4-Related Disease Market Insights, Epidemiology, and Market Forecast- 2034' report provides an in-depth analysis of the disease, including historical and projected epidemiology and market trends in the United States, EU4, the United Kingdom, and Japan. The report highlights key events, emerging therapies, and the competitive landscape for this rare autoimmune condition.

Why it matters

IgG4-related disease is a relatively new and complex condition that can affect multiple organs, leading to significant health complications if left untreated. As awareness and diagnosis of IgG4-RD improve, the market for effective treatments is expected to grow substantially over the next decade, presenting opportunities for pharmaceutical companies to develop innovative therapies.

The details

DelveInsight's report projects the total diagnosed prevalent cases of IgG4-RD in the United States to increase from approximately 56,800 in 2024 to over 76,000 by 2034. Similar trends are expected in the EU4 and UK, where cases are forecasted to rise from 53,550 in 2024 to nearly 72,000 by 2034. The report also highlights the pipeline of emerging therapies, including Zenas BioPharma and Bristol Myers Squibb's obexelimab (XmAb5871), which is currently in Phase III trials for IgG4-RD.

  • On January 29, 2026, Sanofi conducted a study to measure time to IgG4-RD clinical disease flare and other relevant efficacy endpoints.
  • On January 26, 2026, Acepodia Biotech Inc. announced an open-label, multicenter study to assess the safety, efficacy, and persistence of ACE1831 in subjects with IgG4-related disease.

The players

Zenas BioPharma

A biopharmaceutical company developing obexelimab (XmAb5871), a bifunctional monoclonal antibody for the treatment of IgG4-related disease and other autoimmune conditions.

Bristol Myers Squibb

A global biopharmaceutical company that is co-developing obexelimab (XmAb5871) with Zenas BioPharma for the treatment of IgG4-related disease and other autoimmune disorders.

Amgen

A multinational biopharmaceutical company that markets UPLIZNA, a monoclonal antibody approved for the treatment of neuromyelitis optica and IgG4-related disease.

Sanofi

A global pharmaceutical company that is conducting a study to evaluate the efficacy and safety of rilzabrutinib tablets in participants with IgG4-related disease.

Acepodia Biotech Inc.

A clinical-stage biopharmaceutical company that is evaluating the safety, efficacy, and persistence of its investigational therapy ACE1831 in subjects with IgG4-related disease.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.